在接受左心室尾闭塞治疗的患者中,表风险与口服抗凝药相比
Shreya Mandloi1, Kathryn Nunes1, Elliott M Sina1
1Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
The Laryngoscope
|December 11, 2024
概括
与华法林相比,左心房尾阻塞 (LAAO) 在6个月后降低了心房患者的表. 长期机构数据显示,DOAC和华法林使用者在LAAO后的表改善.
科学领域:
- 心脏病学 心脏病学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 医疗器械技术 医疗器械技术
背景情况:
- 抗凝剂 (AC) 与心房动 (AF) 患者的表发生有关.
- 左心房尾阻塞 (LAAO) 为AF患者提供了AC的替代方案.
- 在LAAO与AC相比后面的表风险需要评估.
研究的目的:
- 为了在AF患者中比较LAAO和抗凝药疗法 (DOAC,华法林) 之间的表风险.
- 评估治疗后的短期和长期表发生率和严重程度.
- 评估LAAO在解决先前存在的表症方面的疗效.
主要方法:
- 对TrinetX数据库和机构记录的回顾性分析.
- 包括接受直接口服抗凝剂 (DOAC),华法林或LAAO治疗的AF患者.
- 在治疗开始后的1天-6个月和6个月-3年内对表症几率比率的比较.
主要成果:
- 与华法林相比,LAAO患者的短期表率 (1天-6个月) 较高,可能是由于抗血小板治疗.
- 6个月后,与华法林使用者相比,LAAO患者的表和表需要鼻包装的几率显著降低.
- 在机构上,66%的LAAO患者在1.5年内经历了先前的表.
结论:
- 与华法林相比,LAAO在半年后显著降低了AF患者的表发生频率和严重程度.
- 机构数据表明,在DOAC和华法林患者中,LAAO后的长期表改善.
- 需要进一步的研究来澄清与LAAO后的双重抗血小板治疗相关的表性风险.
相关概念视频
01:30Epistaxis
129
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
129
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468